TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3987781
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg) after standardized breakfast (Phase B)
Study: 15072715
Drug: Acetazolamide 250
Normalized name: acetazolamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250 mg twice daily
Study: 9772584
Drug: Zusanli point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zusanli point immunotherapy (ZPIT)
Study: 9772584
Drug: Conventional desensitization
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional desensitization therapy
Study: 1929138
Drug: Standard drainage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drainage (drain removed when fluid was less than 20 ml per day)
Study: 6812337
Drug: Clebopride 1
Normalized name: clebopride
DrugBank: Clebopride (DB13511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clebopride 1 mg orally at 09.00 h
Study: 25028414
Drug: Intravenous baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous baclofen (3 mg and 5 mg)
Study: 25028414
Drug: Oral baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral baclofen (5 mg and 10 mg)
Study: 17020437
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate (IR MPH) dosed three times daily
Study: 17020437
Drug: Non-stimulant treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-stimulant treatments (e.g., atomoxetine)
Study: 14769594
Drug: Latanoprost (0.005%)
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost (0.005%) once daily
Study: 2865710
Drug: Timolol (0.5%)
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol (0.5%) twice daily
Study: 31251545
Drug: Subdermal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subdermal injection
Study: 11057406
Drug: Peritumoural injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritumoural injection
Study: 8130709
Drug: Brief nurse‐administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief nurse‐administered anti‐smoking intervention
Study: 3298071
Drug: Acyclovir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (800 mg, two 400 mg tablets, five times daily for seven days)
Study: 3298071
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo, five times daily for seven days)
Study: 28259273
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral placebo 2 hours prior to procedure, then placebo twice a day for 5 days)
Study: 26342502
Drug: Sulfur 10%
Normalized name: SULFUR 10% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfur 10% ointment applied for three successive days
Study: 23963058
Drug: Fluoxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (10 mg twice daily)
Study: 23963058
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (600 mg twice daily)
Study: 21654688
Drug: Irinotecan at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan at starting doses of 180 mg m(‐2) for *1/*1, 110 mg m(‐2) for *1/*28, and 90 mg m(‐2) for *28/*28 genotypes; escalated to 450 mg m(‐2) for *1/*1, 390 mg m(‐2) for *1/*28, and 150 mg m(‐2) for *28/*28 genotypes.
Study: 21654688
Drug: Recommended dose
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended dose of 180 mg m(‐2) for irinotecan in FOLFIRI.
Study: 15179649
Drug: Intra-articular injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injections of hyaluronate
Study: 9751463
Drug: Oral glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucocorticoid treatment
Study: 7516979
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (transurethral microwave therapy)
Study: 7516979
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (transurethral microwave therapy) after sham treatment
Study: 3190622
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg dexamethasone orally every 6 h (starting 1 h before take-off)
Study: 3190622
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dexamethasone orally or intramuscularly every 6 h for 24 h
Study: 28401564
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg naltrexone daily for 10 weeks
Study: 28401564
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 10 weeks
Study: 23419135
Drug: Percentage format
Normalized name: formate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percentage format (e.g. 'affects 25% of people')
Study: 23419135
Drug: Frequency format
Normalized name: formate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequency format (e.g. 'affects 1 in 4 people')
Study: 21205874
Drug: Repaglinide (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (6 mg daily)
Study: 16534885
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (800 mg) per month for 6 cycles
Study: 8040707
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard oral hygiene)
Study: 3541622
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of percutaneous estradiol
Study: 3541623
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized progesterone (200 mg) for 12 days of each cycle during the second year
Study: 31432556
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg three times daily
Study: 17561259
Drug: Normal group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal group (no treatment)
Study: 27534634
Drug: Actual supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actual supplement provided (IFA)
Study: 27534634
Drug: Actual supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actual supplement provided (MMN)
Study: 20564081
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy alone (Control group, n=38)
Study: 8866042
Drug: Flurbiprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (200 mg multiple-unit sustained release capsule) after overnight fast
Study: 8866042
Drug: Ibuprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (800 mg erodible sustained release matrix tablet) after overnight fast
Study: 1507928
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg magnesium‐DL‐hydrogen aspartate
Study: 1507928
Drug: magnesium‐L‐hydrogen aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: magnesium‐L‐hydrogen aspartate
Study: 6653132
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg flunitrazepam
Study: 30396363
Drug: Medetomidine (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medetomidine (3.0 μg/kg/h)
Study: 30396363
Drug: Medetomidine (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medetomidine (3.0 μg/kg/h) and Propofol (3.0 mg/kg/h)
Study: 30396363
Drug: Medetomidine (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medetomidine (3.0 μg/kg/h) and Propofol (6.0 mg/kg/h)
Study: 19874329
Drug: Levothyroxine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine plus 5 mg/day desloratadine (suppression group, n = 8)
Study: 19874329
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day desloratadine alone (control group, n = 7)
Study: 12011967
Drug: HR (Paroven,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) 1 g, twice daily for 6 months
Study: 10930636
Drug: Tramadol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 0.5 mg kg(‐1)
Study: 14649346
Drug: Tramadol 1
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1 mg kg(‐1)
Study: 8250358
Drug: 25 ml
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 ml per m2 of body surface area of carbonated 1% lignocaine, 0.25% bupivacaine or a 1 to 1 mixture of both.
Study: 29682022
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate 40 mg injected into each level (Group 1)
Study: 27769202
Drug: Bright Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright Light Therapy (BLT) - 10,000 Lux
Study: 8843961
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (bleomycin, vincristine, mitolactol, methotrexate, 3 courses)
Study: 28404197
Drug: Mercaptopurine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mercaptopurine (1 mg/kg bodyweight, rounded to nearest 25 mg)
Study: 22874843
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium load
Study: 6132613
Drug: Midazolam 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.05 mg kg‐1
Study: 6132613
Drug: Diazemuls 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazemuls 0.15 mg kg‐1
Study: 28945493
Drug: 1.23% acidulated
Normalized name: Nupro APF 1.23% Acidulated Phosphate Fluoride Gel (Bubblegum)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.23% acidulated phosphate fluoride (APF) gel with cold atmospheric plasma (CAP)
Study: 27120271
Drug: 61% ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 61% ethanol solution with 1% chlorhexidine gluconate (ES/CH)
Study: 27120271
Drug: 30% 1‐propanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% 1‐propanol and 45% 2‐propanol solution (MPS)
Study: 27120271
Drug: 70% 2‐propanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70% 2‐propanol solution (IPS)
Study: 16925861
Drug: P supplement
Normalized name: P & S
Approvals — FDA: no, EMA: no, PMDA: no
Description: P supplement 250 mg
Study: 16925861
Drug: P supplement
Normalized name: P & S
Approvals — FDA: no, EMA: no, PMDA: no
Description: P supplement 1500 mg
Study: 10719952
Drug: Propofol administration
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administration in patients older than 60 years
Study: 10719952
Drug: Bolus data
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus data for propofol administration
Study: 9021354
Drug: Sequential step‐up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential step‐up and step‐down protocol
Study: 18687168
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and Propofol combination
Study: 3931136
Drug: lorazepam 2.5
Normalized name: lorazepam 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam 2.5 mg
Study: 31813635
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam accelerated partial breast irradiation (APBI) - 38.5 Gy in ten fractions delivered twice per day over 5-8 days
Study: 15337326
Drug: Olanzapine (5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5‐20 mg) added to mood stabilizer therapy
Study: 15337326
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to mood stabilizer therapy
Study: 12230419
Drug: Extended thromboprophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended thromboprophylaxis with warfarin for 4 more weeks
Study: 12230419
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (stopped warfarin at hospital discharge)
Study: 9686768
Drug: Tolcapone 200
Normalized name: tolcapone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone 200 mg three times a day for 8 weeks
Study: 9686768
Drug: Tolcapone with
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolcapone with oral selegiline (5 mg in the morning and midday) during the second 4 weeks
Study: 11432215
Drug: Acetaminophen plus
Normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen plus cooling blanket (18 degrees C)
Study: 9209244
Drug: Fluvoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100 mg/day during 6 days)
Study: 2893564
Drug: Vecuronium 0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.12 mg/kg
Study: 22374331
Drug: oral sorafenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral sorafenib 400 mg twice a day
Study: 17669023
Drug: rhBMP‐2/ACS (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhBMP‐2/ACS (0.2 mg/mL)
Study: 17669023
Drug: rhBMP‐2/ACS (0.56
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhBMP‐2/ACS (0.56 mg/mL)
Study: 10657735
Drug: Estradiol treatment
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol treatment (0.1 mg 17beta-estradiol daily via transdermal patches)
Study: 10657735
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (placebo via transdermal patches)
Study: 10657735
Drug: Dexamethasone (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1.5 mg) and hCRH (100 microgram)
Study: 7596696
Drug: Unsuccessful biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsuccessful biofeedback treatment
Study: 7352955
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g vitamin C daily (Group III)
Study: 7352955
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g vitamin C daily for the first 20 days (in a separate group of 40 patients with acute myocardial infarction)
Study: 26604721
Drug: GCQID group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCQID group (1,200 mg glucosamine hydrochloride, 60 mg chondroitin sulfate, 45 mg type II collagen peptides, 90 mg quercetin glycosides, 10 mg imidazole peptides, 5 μg vitamin D per day)
Study: 23355041
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of gemcitabine and S‐1
Study: 26308942
Drug: Gemcitabine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine monotherapy
Study: 21188597
Drug: Intranasal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal steroid (INS) therapy (mometasone furoate)
Study: 12728284
Drug: Etanercept (TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (TNF antagonist)
Study: 10417520
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin applied for 24 h
Study: 8936891
Drug: School-based, nurse-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based, nurse-administered relaxation training
Study: 1660823
Drug: Azithromycin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1.5 g in five or six doses over 5 days)
Study: 1660824
Drug: Erythromycin (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (14 or 20 g in 28 or 40 doses over 7 or 10 days)
Study: 1660824
Drug: Amoxycillin (10.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (10.5 g in 21 doses over 7 days)
Study: 7076116
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg per kg per day of ursodeoxycholic acid (UDCA) for 45 to 60 days
Study: 7076116
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5 mg per kg per day of chenodeoxycholic acid (CDCA) and 5 mg per kg per day of ursodeoxycholic acid (UDCA) for 45 to 60 days
Study: 7076116
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg per kg per day of chenodeoxycholic acid (CDCA) for 45 to 60 days
Study: 7076116
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg per kg per day of chenodeoxycholic acid (CDCA)
Study: 14587303
Drug: Val 160
Normalized name: Val
DrugBank: Valine (DB00161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Val 160 mg
Study: 14587303
Drug: Val 160
Normalized name: Val
DrugBank: Valine (DB00161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Val 160 mg/HCTZ 12.5 mg
Study: 14587303
Drug: Val 160
Normalized name: Val
DrugBank: Valine (DB00161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Val 160 mg/HCTZ 25 mg
Study: 10491452
Drug: Misoprostol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (800 or 1600 microg daily)
Study: 1790547
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg orally every 12 hours for 10 days
Study: 29048966
Drug: Weekly SMS
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly SMS message group
Study: 29048966
Drug: Weekly SMS
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly SMS message with response option group
Study: 25109720
Drug: Gamma oryzanol
Normalized name: GAMMA ORYZANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma oryzanol supplementation (600 mg/day)
Study: 23045591
Drug: Tamoxifen and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen and exemestane treatment
Study: 16055868
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Tiotropium + Formoterol) q.d.
Study: 9545143
Drug: Statins (HMG-coenzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins (HMG-coenzyme A reductase inhibitors)
Study: 8006330
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g oral ARG (group D)
Study: 8006330
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g i.v. ARG (group C)
Study: 20516313
Drug: Active motion
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active motion therapy (place-and-hold)
Study: 20516313
Drug: Passive motion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive motion therapy
Study: 8831305
Drug: Aprotinin treatment
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin treatment
Study: 10437237
Drug: Fufang Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fufang Danshen Tablet
Study: 3534568
Drug: 14-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-valent pneumococcal capsular polysaccharide vaccine
Study: 2681554
Drug: Ifosfamide plus
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide plus doxorubicin (doxorubicin 60 mg/m2 by continuous push, ifosfamide 5.0 g/m2 by continuous infusion over 24 hours with mesna 7.5 g/m2 over 36 hours, courses every 3 weeks)
Study: 30572837
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg tramadol
Study: 30819084
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment with clozapine
Study: 16603829
Drug: Lipid-lowering agents
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering agents
Study: 18295467
Drug: Zinc picolinate
Normalized name: Zinc picolinate
DrugBank: Zinc picolinate (DB11175)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc picolinate supplementation (22 mg daily for 8 weeks)
Study: 8807761
Drug: Intensive antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive antibiotic therapy plus early ultrasound-guided vaginal drainage
Study: 8807761
Drug: Intensive antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive antibiotic therapy alone
Study: 23797954
Drug: Oral ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ascorbic acid (AA) 4 g/d
Study: 14581270
Drug: Letrozole as
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole as first-line therapy
Study: 14581270
Drug: Tamoxifen as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen as first-line therapy
Study: 20380750
Drug: Traumeel tablets
Normalized name: TRAUMEEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traumeel tablets
Study: 16131466
Drug: Subcutaneous block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous block
Study: 12704016
Drug: Comprehensive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comprehensive intervention plus 2 monthly booster sessions
Study: 1101933
Drug: Total body
Normalized name: Total Body Massager Item
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total body radiation therapy
Study: 25912697
Drug: Serelaxin 30
Normalized name: serelaxin
DrugBank: Serelaxin (DB05794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serelaxin 30 µg·kg(‐1)·day(‐1)
Study: 19170716
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg) for 16 weeks
Study: 15289797
Drug: Rivastigmine 6-12
Normalized name: rivastigmine 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine 6-12 mg/day
Study: 10979055
Drug: Diuretics, beta-blockers,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, calcium antagonists
Study: 1397666
Drug: Nicardipine hydrochloride/HCTZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine hydrochloride/HCTZ (30 mg nicardipine three times daily)